Remimazolam

Remimazolam
Clinical data
Trade names	Byfavo
Other names	CNS-7056
AHFS/Drugs.com	Monograph
License data	US DailyMed: Remimazolam;
Routes of; administration	Intravenous
ATC code	N05CD14 (WHO) ;
Legal status
Legal status	CA: Schedule IV; DE: Anlage III (Special prescription form required); UK: Under Psychoactive Substances Act; US: Schedule IV; EU: Rx-only;
Pharmacokinetic data
Elimination half-life	45 - 70 minutes
Identifiers
	IUPAC name methyl 3-[(4S)-8-bromo-1-methyl-6-(pyridin-2-yl)-4H-imidazo[1,2-a][1,4]benzodiazepin-4-yl]propanoate;
CAS Number	308242-62-8 ;
PubChem CID	9867812;
DrugBank	DB12404 ;
ChemSpider	8043503 ;
UNII	7V4A8U16MB;
KEGG	D11788; as salt: D10194;
ChEMBL	ChEMBL4297526;
CompTox Dashboard (EPA)	DTXSID20953024 ;
Chemical and physical data
Formula	C21H19BrN4O2
Molar mass	439.313 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC(=O)CC[C@@H]1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc21;
	InChI InChI=1S/C21H19BrN4O2/c1-13-12-24-21-17(7-9-19(27)28-2)25-20(16-5-3-4-10-23-16)15-11-14(22)6-8-18(15)26(13)21/h3-6,8,10-12,17H,7,9H2,1-2H3/t17-/m0/s1 ; Key:CYHWMBVXXDIZNZ-KRWDZBQOSA-N ;
	(what is this?) (verify)

Remimazolam, sold under the brand name Byfavo, is a medication for the induction and maintenance of procedural sedation in adults for invasive diagnostic or surgical procedures lasting 30 minutes or less. It is a benzodiazepine drug, developed by PAION AG in collaboration with several regional licensees as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in the induction of anesthesia and conscious sedation for minor invasive procedures.

Remimazolam was found to have both a more rapid onset and a shorter duration than midazolam, and human clinical trials showed a faster recovery time and predictable, consistent pharmacokinetics, suggesting some advantages over existing drugs for these applications.

The most common side effects for procedural sedation include low blood pressure, high blood pressure, diastolic hypertension, systolic hypertension, low blood oxygen level, and diastolic hypotension.

Remimazolam was approved for medical use in the United States in July 2020, and in the European Union in March 2021.